NasdaqGS - Nasdaq Real Time Price • USD
Amgen Inc. (AMGN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:58 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 21 | 20 | 27 | 26 |
Avg. Estimate | 3.61 | 4.65 | 18.16 | 19.57 |
Low Estimate | 3.09 | 4.35 | 17.57 | 17.33 |
High Estimate | 4.54 | 5.24 | 19.08 | 21.47 |
Year Ago EPS | 3.98 | 5 | 17.38 | 18.16 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 20 | 18 | 28 | 27 |
Avg. Estimate | 6.93B | 7.73B | 30.71B | 31.79B |
Low Estimate | 6.81B | 7.55B | 30.12B | 30.32B |
High Estimate | 7.15B | 7.86B | 31.17B | 34.42B |
Year Ago Sales | 6.11B | 6.99B | 26.27B | 30.71B |
Sales Growth (year/est) | 13.50% | 10.60% | 16.90% | 3.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 3.85 | 4.49 | 4.67 | 4.29 |
EPS Actual | 3.98 | 5 | 4.96 | 4.39 |
Difference | 0.13 | 0.51 | 0.29 | 0.1 |
Surprise % | 3.40% | 11.40% | 6.20% | 2.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 3.61 | 4.65 | 18.16 | 19.57 |
7 Days Ago | 3.65 | 4.67 | 18.35 | 19.74 |
30 Days Ago | 3.67 | 4.6 | 18.07 | 19.53 |
60 Days Ago | 3.99 | 4.99 | 19.56 | 21.13 |
90 Days Ago | 4.07 | 4.76 | 18.47 | 19.83 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | 1 | 1 |
Up Last 30 Days | 5 | 4 | 5 | 7 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 3 | 2 | 4 | 3 |
Growth Estimates
CURRENCY IN USD | AMGN | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -9.30% | -- | -- | 6.50% |
Next Qtr. | -7.00% | -- | -- | 12.00% |
Current Year | 4.50% | -- | -- | 5.30% |
Next Year | 7.80% | -- | -- | 13.10% |
Next 5 Years (per annum) | 4.89% | -- | -- | 11.09% |
Past 5 Years (per annum) | 5.71% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | UBS: Neutral to Neutral | 4/17/2024 |
Maintains | TD Cowen: Buy to Buy | 4/17/2024 |
Reiterates | Truist Securities: Buy to Buy | 4/12/2024 |
Reiterates | RBC Capital: Outperform to Outperform | 4/3/2024 |
Maintains | Goldman Sachs: Buy to Buy | 2/8/2024 |
Maintains | RBC Capital: Outperform to Outperform | 2/7/2024 |
Related Tickers
MRK Merck & Co., Inc.
131.20
+0.37%
BIIB Biogen Inc.
208.90
+3.18%
GILD Gilead Sciences, Inc.
65.42
+0.23%
ABBV AbbVie Inc.
159.62
-4.58%
JNJ Johnson & Johnson
146.14
-0.46%
BMY Bristol-Myers Squibb Company
44.85
+0.34%
LLY Eli Lilly and Company
733.51
+1.19%
AZN AstraZeneca PLC
75.17
+0.19%
NVS Novartis AG
97.44
-1.64%
SNY Sanofi
49.13
-0.47%